Delivery Order SPE2DB20D9766-SPE2DB24FC1GC

Award Date 6/13/24
Potential Completion Date 6/14/24
Potential Value $9.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $6,410.52 contract is for the delivery of fluticasone propionate HFA 220 mcg 12 gm inhalers. It is part of a larger $499,999,999 indefinite delivery contract (IDC) between DMS Pharmaceutical Group and DLA under the SPE2DB program, which provides a comprehensive range of pharmaceutical...
This is a $2,071.80 firm fixed-price delivery order contract awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA). The contract is for the delivery of fluticasone propionate HFA 110 mcg 12g inhalers to support the recurring medical supply needs of military health facilities. The delivery order was issued under DMS Pharmaceutical Group's larger $499,999,999 indefinite delivery contract (IDC) with the DLA, which...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,381.20 order is for the supply of fluticasone propionate HFA 110 mcg 12 g inhalers, with a period of performance through May 13, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows...
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,883.80 award is for the supply of fluticasone propionate HFA 110 mcg 12 gram inhalers, with a period of performance through February 20, 2024. The order was placed by the Defense Logistics Agency (DLA), a defense agency, under their SPE2DB program. This is an Indefinite Delivery Contract (IDC) with a ceiling value of...
This is a delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,342.40 firm fixed-price contract was awarded by the Defense Logistics Agency (DLA) for the supply of fluticasone propionate HFA 44 mcg 10.6 gm inhalers. The delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This IDC...
The Defense Logistics Agency awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide 4,563,347,855 units of fluticasone propionate HFA 220 mcg 12 gm inhalers. The contract has a potential value of $11,726.80 and a completion date of January 11, 2024. DMS Pharmaceutical Group Inc. is a leading pharmaceutical wholesaler that holds various federal contracts and indefinite delivery vehicles to supply pharmaceuticals and medical products...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,381.20 contract is for the delivery of Fluticasone Prop HFA 110 MCG 12GM, a branded pharmaceutical product. The delivery order was issued under a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at up to $499,999,999, which allows the...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) under the Medical Supply Chain division to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $2,762.40 contract is for the delivery of fluticasone 110mcg inhalation aerosol product. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA to...
This is a $4,917.21 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract is for the supply of Fluticasone Propionate HFA 220 mcg 12 gram inhalers, with a period of performance through August 2024. This delivery order is associated with a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 that AmerisourceBergen holds with DLA Troop Support Medical for a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order, valued at $1,956.70, is for the delivery of fluticasone propionate HFA 110 mcg inhalation aerosol. The contract has a firm fixed-price pricing type and runs through May 16, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with DLA under the...
  • SPE2DB20D9766
    Indefinite Delivery Contract
  • SPE2DB20D9766-SPE2DB24FC1GC
    Delivery Order

This is a $9,885.20 firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA) on June 13, 2024. The order is for the supply of fluticasone propionate HFA 220 mcg 12 gram inhalers, with a June 14, 2024 ultimate completion date. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group Inc. with the DLA under the SPE2DB program, which allows the DLA to issue orders for a comprehensive range of pharmaceutical products to support the recurring medical supply needs of military health facilities worldwide. The contract does not have a set-aside designation.

Generated 9/12/24, 11:00 AM